Drug intelligence / Profile preview

MCS2103

Development stage: Preclinical
Lead developer: PharmaCept
Modality: Hydrogel Systems → Drug Delivery Systems
Administration: Topical

Overview

MCS2103 is a hydrogel-based product in the design verification stage, developed by Magle Pharmacept for advanced wound care. It is formulated as an easy-to-use and effective hydrogel, designed to promote wound healing. The product utilizes GelSpheres technology and is intended for use in the management of wounds, likely by providing a moist environment conducive to healing and potentially delivering active agents locally.

Beyond the preview

Go deeper on MCS2103.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MCS2103.

Explore the full profile